Skip to content
Angioedema News logo Newsletter
Newsletter
  • About angioedema
    What is angioedema?
    Types
    • Acquired angioedema
    • Hereditary angioedema
    • Idiopathic angioedema
    • Acute allergic angioedema
    • Drug-induced nonallergic angioedema
    Causes
    Diagnosis
    Symptoms
    Living with angioedema
    • Diet
  • Treatments
    Approved treatments
    Experimental treatments
  • Featured topics
    Taking action with HAE
    • HAE and advocacy
    • Next steps after an HAE diagnosis
    • Beyond swelling: Other HAE symptoms
    • Treatment and management of HAE attacks
    • Raising a child with HAE
    • HAE triggers and prevention plan
    • HAE and preventive treatment
    • Bracing for a diagnosis
    • HAE and stress
    • Angioedema and skin care
    • View all
    Navigating HAE
    • HAE pool prep
    • HAE journey
    • HAE genetics
    • HAE and factor XII
    • Managing HAE medications
    • HAE and women
    • Traveling with HAE
    • HAE awareness and advocacy
    • Talking to your doctor
    • Self-care tips for caregivers
    • View all
  • News
  • Columns
    Dancing with Rare Disease — Natalie Sirota
    From the Caregiver’s HAErt — Danita LaShelle Jones
    Living Rare, Speaking Loud — Hollie Amadio
  • What can we help you find today?

Navenibart for hereditary angioedema

Last updated July 2, 2025, by Andrea Lobo, PhD
✅ Fact-checked by Joana Carvalho, PhD

Administration
Clinical trials
Side effects

 

What is navenibart for hereditary angioedema?

Navenibart, formerly known as STAR-0215, is an experimental injectable therapy that is being developed as a prophylactic treatment to prevent swelling attacks in people with hereditary angioedema (HAE).

It is an antibody-based therapy that’s designed to block the activity of kallikrein, an enzyme that is overactive in HAE and increases the production and release of bradykinin — a signaling molecule that causes blood vessels to widen and leak fluid into tissues, causing swelling. By inhibiting kallikrein, navenibart is expected to reduce bradykinin levels, thus preventing HAE swelling attacks.

The therapy, administered via subcutaneous, or under-the-skin, injections, is being developed by Astria Therapeutics and is currently being tested in a Phase 3 clinical trial.

Navenibart has received orphan drug status for HAE in both the U.S. and Europe. These designations aim to speed the development and regulatory review of treatments for rare diseases.

Therapy snapshot

Treatment name: Navenibart
Administration: Subcutaneous injection
Clinical testing: Currently in Phase 3 testing

 

How will navenibart be administered?

In clinical trials involving HAE patients, navenibart has been administered via subcutaneous injections, generally once every three or six months, at doses of 300 to 600 mg, following several dosing regimens.

Navenibart in clinical trials

Navenibart has been tested in a series of clinical trials, including a Phase 1b/2 study and its extension study, involving adults with HAE type 1 or 2. Available data from these studies showed that navenibart was safe and able to reduce the rate of monthly swelling attacks.

  • ALPHA-STAR (NCT05695248), where navenibart was found to be safe and well tolerated, and able to reduce the rate of monthly swelling attacks by 90% to 95% after six months, when given once or twice, at doses of 300 mg to 600 mg.
  • ALPHA-SOLAR extension study (NCT06007677), where navenibart continued to safely reduce the rate of monthly swelling attacks in patients who had completed ALPHA-STAR. Initial results from the extension study showed the therapy had reduced the monthly rate of HAE attacks by a mean of 92% over the course of approximately 10 months, when given at a dose of 300 mg every three months or 600 mg every six months.

Navenibart’s safety and efficacy against a placebo are currently being assessed in a Phase 3 clinical trial called ALPHA-ORBIT (NCT06842823), which is enrolling up to 145 adolescents and adults, ages 12 and older, with HAE type 1 or 2. Top-line data are expected in 2027.

Common side effects of navenibart

The most common treatment-emergent side effects reported in clinical trials testing navenibart in HAE patients were:

  • injection site reactions, including redness, swelling, itching, and rash
  • cold-like symptoms (nasopharyngitis)
  • sinus inflammation (sinusitis)
  • urinary tract infections
  • skin laceration
  • nasal congestion
  • headache.

Angioedema News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Recent Posts

  • Switching to donidalorsen brings fewer HAE swelling attacks: Study
  • At this year’s HAEA National Summit, we all felt like family
  • Woman given HAE type 1 diagnosis after 20-year delay: Case report
  • Ekterly OK’d as on-demand HAE swelling attack treatment in UK
  • Pharvaris to seek FDA approval of HAE treatment deucrictibant


Related articles

  1. The words 'clinical trials' are pictured in all capital letters, with a handful of oral medications at the top left corner and a heart monitor reading at the bottom right.
    July 24, 2025 News by Marisa Wexler, MS

    Switching to donidalorsen brings fewer HAE swelling attacks: Study

  2. Banner for
    July 22, 2025 Columns by Natalie Sirota

    At this year’s HAEA National Summit, we all felt like family

  3. An analog alarm clock is pictured.
    July 21, 2025 News by Patricia Inácio, PhD

    Woman given HAE type 1 diagnosis after 20-year delay: Case report

  4. Multiple hands in a row are showing the thumbs-up sign.
    July 17, 2025 News by Lindsey Shapiro, PhD

    Ekterly OK’d as on-demand HAE swelling attack treatment in UK

  5. Two hands, a stethoscope, and some medications surround a clinical trial graph showing positively trending results.
    July 14, 2025 News by Lila Levinson, PhD

    Pharvaris to seek FDA approval of HAE treatment deucrictibant

  6. Illustration of pills in a cup next to an alarm clock.
    July 10, 2025 News by Michela Luciano, PhD

    DPP4 inhibitors for type 2 diabetes found not to raise angioedema risk

Swipe left to view more
Envelope icon

Subscribe to our newsletter

Get regular updates to your inbox.

This field is for validation purposes and should be left unchanged.

Bionews, Inc.

3 W Garden St
Suite 700
Pensacola, FL 32502
Website: bionews.com
Email: [email protected]
Phone: 1-800-936-1363

  • About Us
  • Leadership
  • Our Culture
  • Editorial Policy
  • Advertising Policy
  • Corrections Policy
  • Terms of Service
  • Privacy Policy
  • Careers
  • Contact Us
Disclaimer

This site is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2013-2025 All rights reserved.